(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 43.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Axsome Therapeutics's revenue in 2026 is $776,569,000.On average, 24 Wall Street analysts forecast AXSM's revenue for 2026 to be $51,563,153,431, with the lowest AXSM revenue forecast at $44,894,027,683, and the highest AXSM revenue forecast at $56,623,664,258. On average, 24 Wall Street analysts forecast AXSM's revenue for 2027 to be $82,290,265,078, with the lowest AXSM revenue forecast at $59,556,990,066, and the highest AXSM revenue forecast at $96,014,039,394.
In 2028, AXSM is forecast to generate $122,518,733,302 in revenue, with the lowest revenue forecast at $85,590,256,612 and the highest revenue forecast at $193,651,884,146.